The European pharmaceutical industry is facing multiple challenges; chief among them is manufacturing downtime, with a single interruption to production having the potential to cost millions.
For many commentators, the solution is to embrace artificial intelligence (AI). Consultancies such as McKinsey estimate that AI could unlock $60–110 billion in value per year for the sector.
Here, AI is already making inroads into pharma manufacturing, particularly in the areas of quality control and process validation.
However, for these assessments of the impact of AI to meet expectations, it will have to overcome challenges in data quality, regulatory complexities and the high costs of integration and maintenance.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.